EMD-26369

Single-particle
25.0 Å
EMD-26369 Deposition: 04/03/2022
Map released: 27/04/2022
Last modified: 17/01/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-26369

SARS-2 CoV 6P Mut7 in complex with Fab CC25.36

EMD-26369

Single-particle
25.0 Å
EMD-26369 Deposition: 04/03/2022
Map released: 27/04/2022
Last modified: 17/01/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens
Sample: SARS-2 CoV 6P Mut7 in complex with Fab CC25.36

Deposition Authors: Torres JL , Ward AB
Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses.
PUBMED: 35654851
DOI: doi:10.1038/s41590-022-01222-1
ISSN: 1529-2916
Abstract:
The emergence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and potential future spillovers of SARS-like coronaviruses into humans pose a major threat to human health and the global economy. Development of broadly effective coronavirus vaccines that can mitigate these threats is needed. Here, we utilized a targeted donor selection strategy to isolate a large panel of human broadly neutralizing antibodies (bnAbs) to sarbecoviruses. Many of these bnAbs are remarkably effective in neutralizing a diversity of sarbecoviruses and against most SARS-CoV-2 VOCs, including the Omicron variant. Neutralization breadth is achieved by bnAb binding to epitopes on a relatively conserved face of the receptor-binding domain (RBD). Consistent with targeting of conserved sites, select RBD bnAbs exhibited protective efficacy against diverse SARS-like coronaviruses in a prophylaxis challenge model in vivo. These bnAbs provide new opportunities and choices for next-generation antibody prophylactic and therapeutic applications and provide a molecular basis for effective design of pan-sarbecovirus vaccines.